$Array生物制药_老虎社区_美港股上老虎

2019-07-15

$Array生物制药(ARRY)$ Array BioPharma公布了该公司开发的三联疗法在治疗携带BRAF V600E突变的转移性结直肠癌（mCRC）患者的3期临床试验结果。这一三联疗法由BRAF抑制剂Braftovi（encorafenib）、MEK抑制剂Mektovi（binimetinib）和抗EGFR抗体Erbitux（cetuximab）构成。试验结果表明，三联疗法与化疗对照组相比，显著提高患者的总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。Array公司计划在今年递交监管申请。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

蔚来未来
2019-07-15
蔚来未来
[强]

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":999344953,"tweetId":"999344953","gmtCreate":1563146958172,"gmtModify":1704704775868,"author":{"id":3513759580005971,"idStr":"3513759580005971","authorId":3513759580005971,"authorIdStr":"3513759580005971","name":"肥皂我只捡舒肤佳","avatar":"https://static.tigerbbs.com/2247276028a571a208059d8b3573ada3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/ARRY\">$Array生物制药(ARRY)$</a>&nbsp;Array BioPharma公布了该公司开发的三联疗法在治疗携带BRAF V600E突变的转移性结直肠癌（mCRC）患者的3期临床试验结果。这一三联疗法由BRAF抑制剂Braftovi（encorafenib）、MEK抑制剂Mektovi（binimetinib）和抗EGFR抗体Erbitux（cetuximab）构成。试验结果表明，三联疗法与化疗对照组相比，显著提高患者的总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。Array公司计划在今年递交监管申请。</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/ARRY\">$Array生物制药(ARRY)$</a>&nbsp;Array BioPharma公布了该公司开发的三联疗法在治疗携带BRAF V600E突变的转移性结直肠癌（mCRC）患者的3期临床试验结果。这一三联疗法由BRAF抑制剂Braftovi（encorafenib）、MEK抑制剂Mektovi（binimetinib）和抗EGFR抗体Erbitux（cetuximab）构成。试验结果表明，三联疗法与化疗对照组相比，显著提高患者的总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。Array公司计划在今年递交监管申请。</body></html>","text":"$Array生物制药(ARRY)$ Array BioPharma公布了该公司开发的三联疗法在治疗携带BRAF V600E突变的转移性结直肠癌（mCRC）患者的3期临床试验结果。这一三联疗法由BRAF抑制剂Braftovi（encorafenib）、MEK抑制剂Mektovi（binimetinib）和抗EGFR抗体Erbitux（cetuximab）构成。试验结果表明，三联疗法与化疗对照组相比，显著提高患者的总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。Array公司计划在今年递交监管申请。","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/999344953","repostId":0,"isVote":1,"tweetType":1,"viewCount":2407,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ARRY"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":370,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":1706510,"commentId":"1706510","gmtCreate":1563175079548,"gmtModify":1563175079548,"authorId":3479274817508714,"author":{"id":3479274817508714,"idStr":"3479274817508714","authorId":3479274817508714,"name":"蔚来未来","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":999344953,"objectIdStr":"999344953","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"[强]","text":"[强]","html":"[强]","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/999344953"}